Work

Phase Ib trial of ALT-803, an IL-15 superagonist, plus Bacillus Calmette Guerin (BCG) for the treatment of patients with BCG-naïve non-muscle-invasive bladder cancer (NMIBC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.2_suppl.470

Authors: Charles Joel Rosser, Jeffrey Nix, Liza Hernandez, Peter R. Rhode, Hing C. Wong

Institutions: University of Hawaii Cancer Center, University of Alabama at Birmingham, Altor BioScience (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589588487

Cites:

Cited by: 2

Related to: 10